Ignite Creation Date:
2024-05-05 @ 6:39 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00525018
Status:
UNKNOWN
Last Update Posted:
2007-09-05
First Post:
2007-09-03
Brief Title:
Brain Activation During Thermal Stimulation in Neuropathic Pain
Sponsor:
National Taiwan University Hospital
Organization:
National Taiwan University Hospital
Study Overview
Official Title:
Brain Activation During Thermal Stimulation in Neuropathic Pain
Status:
UNKNOWN
Status Verified Date:
2007-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with peripheral neuropathy frequently exhibit treatment-refractory neuropathic pain Although both peripheral and central determinants are recognized for the pathophysiological basis of neuropathic pain following peripheral injury the modulating effect on pain processing in brain by peripheral mechanisms remains elusive Here we will systematically compare the sensory symptoms and brain activation to painful heat stimulation applied to the foot dorsum between patients with peripheral neuropathy and healthy controls Functional magnetic resonance imaging will be used to define brain activation to thermal stimulation with noxious heat and innocuous warm thermal stimuli applied by contact heat stimulator Brain activation during thermal stimulation in patients with neuropathic pain will be clarified and we will also analyze the potential relationships between the topography quality and intensity of the different painful symptoms and the magnitude and pattern of brain activation during thermal stimulation This will add in our understanding in the pathophysiology of brain modulation in pain and provide clinically useful message toward the potential therapeutics in the management of neuropathic pain
Detailed Description:
Patients with peripheral neuropathy and healthy volunteers will be recruited in this study Peripheral neuropathy is defined according to the neuropathic symptoms and signs Informed consent will be approved by the Ethical Committee of the National Taiwan University Hospital and obtained from each subject
To assess the severity of different neuropathic symptoms such as spontaneous ongoing and paroxysmal pain evoked pain paraesthesia and dysaesthesia patients with neuropathic pain will fill out the Neuropathic Pain Symptom Inventory Each subject will receive detailed sensory examination to evaluate the integrity of sensory fibers To measure thresholds of thermal and vibratory sensations we will perform quantitative sensory testing by the method of level using a Thermal Sensory Analyser and Vibratory Sensory Analyser Medoc Advanced Medical System Minneapolis MN USA following an established protocol We will use a contact heat stimulator to deliver thermal stimulation Noxious and innocuous heat temperatures will be applied within the right foot dorsum Several pretests will be applied before CHEP recording to eliminate expectation effects To avoid sensitization and desensitization low intensity stimuli will precede high intensity stimuli at each block
Functional magnetic resonance imaging fMRI will be performed on a 3-T MR machine Sonata Siemens Erlangen Germany A high resolution T1 weighted scan of the entire brain in trans-axial orientation will be obtained to provide anatomical information for the superimposed functional activation maps Echo Planar Imaging will be used for the acquisition of the functional data Each imaging session will be consisted of one high-resolution anatomical scan and three functional scanning runs with 5-min intersession interval During the scanning several thermal stimuli will be applied by CHEP stimulator to the right dorsal foot To avoid sensitization the stimulation site will be changed slightly after each stimulus After 12-s stimulation the temperature will be cooling with a subsequent 36-s interstimulus interval After each fMRI session subjects will be asked to rate the intensity and unpleasantness of received pain stimulus The average rating values will be indicated after the scan on a computer driven visual analogue scale ranging from 0 to 10 0 no pain 1 slight intense 2 mild intense 3 moderate intense 4 slight pain 5 mild pain 6 moderate pain 7 moderate-strong pain 8 strong pain 9 severe pain 10 unbearable pain and the intensity and unpleasantness of received pain will be assessed using the Short-Form McGill Pain Questionnaire
All data will be processed using the Statistical Parametric Mapping software SPM2 fMRI data series will be realigned and resliced with sinc interpolation to correct for motion artifacts Scans with sudden head movements of more than 2 mm will be omitted To enable intersubject analysis the functional data will be coregistered to the anatomical scan and transformed into a reference space according to the MNI template of SPM2 by normalization using sinc interpolation The resampled voxel volume of the normalized images is 2 x 2 x 2 mm Subsequently data will be smoothed with an isotropic Gaussian kernel of 8 mm full-width at half maximum to reduce high frequency noise and to account for anatomical variances Condition-specific effects will be estimated with the general linear model using a boxcar approach convolved with the hemodynamic response function High pass filtering will remove low frequency noise and low pass filtering will account for serial autocorrelations of the data
We will analyze the data on an individual subject per subject basis and across subjects group analysis using a cross-subjects variance random effect analysis Data from each stimulation will be pooled for group statistical comparisons A single design matrix including 3 sessions of all subjects will be generated due to the limited number of experiments representing a fixed-effects model analysis Statistical parametric maps will be generated as t-contrasts and corrected for multiple comparisons according to the random field theory with P 005 The threshold for the Z maps is 309 P 0001 for individual subject analysis Significant clusters have to show a minimum extension volume of 10 voxels
To assess the severity of different neuropathic symptoms such as spontaneous ongoing and paroxysmal pain evoked pain paraesthesia and dysaesthesia patients with neuropathic pain will fill out the Neuropathic Pain Symptom Inventory Each subject will receive detailed sensory examination to evaluate the integrity of sensory fibers To measure thresholds of thermal and vibratory sensations we will perform quantitative sensory testing by the method of level using a Thermal Sensory Analyser and Vibratory Sensory Analyser Medoc Advanced Medical System Minneapolis MN USA following an established protocol We will use a contact heat stimulator to deliver thermal stimulation Noxious and innocuous heat temperatures will be applied within the right foot dorsum Several pretests will be applied before CHEP recording to eliminate expectation effects To avoid sensitization and desensitization low intensity stimuli will precede high intensity stimuli at each block
Functional magnetic resonance imaging fMRI will be performed on a 3-T MR machine Sonata Siemens Erlangen Germany A high resolution T1 weighted scan of the entire brain in trans-axial orientation will be obtained to provide anatomical information for the superimposed functional activation maps Echo Planar Imaging will be used for the acquisition of the functional data Each imaging session will be consisted of one high-resolution anatomical scan and three functional scanning runs with 5-min intersession interval During the scanning several thermal stimuli will be applied by CHEP stimulator to the right dorsal foot To avoid sensitization the stimulation site will be changed slightly after each stimulus After 12-s stimulation the temperature will be cooling with a subsequent 36-s interstimulus interval After each fMRI session subjects will be asked to rate the intensity and unpleasantness of received pain stimulus The average rating values will be indicated after the scan on a computer driven visual analogue scale ranging from 0 to 10 0 no pain 1 slight intense 2 mild intense 3 moderate intense 4 slight pain 5 mild pain 6 moderate pain 7 moderate-strong pain 8 strong pain 9 severe pain 10 unbearable pain and the intensity and unpleasantness of received pain will be assessed using the Short-Form McGill Pain Questionnaire
All data will be processed using the Statistical Parametric Mapping software SPM2 fMRI data series will be realigned and resliced with sinc interpolation to correct for motion artifacts Scans with sudden head movements of more than 2 mm will be omitted To enable intersubject analysis the functional data will be coregistered to the anatomical scan and transformed into a reference space according to the MNI template of SPM2 by normalization using sinc interpolation The resampled voxel volume of the normalized images is 2 x 2 x 2 mm Subsequently data will be smoothed with an isotropic Gaussian kernel of 8 mm full-width at half maximum to reduce high frequency noise and to account for anatomical variances Condition-specific effects will be estimated with the general linear model using a boxcar approach convolved with the hemodynamic response function High pass filtering will remove low frequency noise and low pass filtering will account for serial autocorrelations of the data
We will analyze the data on an individual subject per subject basis and across subjects group analysis using a cross-subjects variance random effect analysis Data from each stimulation will be pooled for group statistical comparisons A single design matrix including 3 sessions of all subjects will be generated due to the limited number of experiments representing a fixed-effects model analysis Statistical parametric maps will be generated as t-contrasts and corrected for multiple comparisons according to the random field theory with P 005 The threshold for the Z maps is 309 P 0001 for individual subject analysis Significant clusters have to show a minimum extension volume of 10 voxels
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None